Is there a difference between ferrous sulfate 65 mg delayed‑release (enteric‑coated) and regular (immediate‑release) ferrous sulfate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Delayed-Release vs Regular Ferrous Sulfate: Key Differences

Regular (immediate-release) ferrous sulfate is superior to delayed-release (enteric-coated) formulations for treating iron deficiency, and modified-release preparations are explicitly not recommended for prescribing.

Critical Distinction: Absorption

The most important difference between these formulations is iron bioavailability:

  • Regular ferrous sulfate tablets release iron in the proximal small intestine where absorption is optimal
  • Delayed-release/enteric-coated tablets are designed to bypass the stomach and release iron further down the GI tract, resulting in significantly reduced absorption 1

A stable isotope study demonstrated that iron absorption from enteric-coated ferrous sulfate was only 3.5% compared to 12% from uncoated tablets (p<0.05) in iron-deficient women 1. This represents a 70% reduction in bioavailability.

Guideline Position

The British Society of Gastroenterology explicitly states that modified-release (MR) preparations are "less suitable for prescribing" 2. This designation appears consistently in their comprehensive 2021 guidelines on iron deficiency anemia management.

The guidelines list both formulations but clearly mark MR preparations with a footnote indicating they should be avoided 2.

Why Enteric-Coating Fails

The physiological rationale is straightforward:

  • Iron is primarily absorbed in the duodenum and proximal jejunum
  • Enteric coatings prevent dissolution until the tablet reaches more distal intestinal segments
  • By the time the coating dissolves, the tablet has passed the optimal absorption zone
  • This defeats the purpose of iron supplementation despite theoretical GI tolerability benefits 1

The Tolerability Myth

Enteric-coated formulations were developed to reduce GI side effects, but this benefit is largely theoretical and comes at an unacceptable cost to efficacy. While one older study from 1976 suggested slightly better absorption from slow-release preparations 3, this contradicts modern isotope studies and current guideline recommendations.

A concerning practice pattern exists: 96% of Canadian pharmacies dispensed enteric-coated preparations when generic ferrous sulfate was prescribed 4, meaning patients may unknowingly receive inferior formulations.

Cost Considerations

Regular ferrous sulfate (200 mg tablet, 65 mg elemental iron) costs approximately £1.00 per 28 days, while MR preparations cost £2.58-£3.95 per 28 days 2. You're paying 2-4 times more for significantly worse absorption.

Clinical Recommendation Algorithm

Use regular (immediate-release) ferrous sulfate as first-line:

  • Standard dose: 65 mg elemental iron once daily 2
  • Take on empty stomach for optimal absorption (or with food if not tolerated) 5
  • Avoid tea/coffee within 1 hour 5
  • Consider vitamin C co-administration 5

If GI side effects occur with regular formulation:

  • Switch to alternate-day dosing (not enteric-coated) 2
  • Reduce to lower daily dose (50 mg elemental iron)
  • Consider different iron salt (ferrous fumarate, ferrous gluconate)
  • Consider ferric maltol if traditional salts fail 2
  • Consider IV iron if oral intolerance persists 2

Never switch to enteric-coated/delayed-release as a solution for side effects - the reduced absorption negates any tolerability benefit.

Common Pitfall

The most significant clinical error is prescribing or dispensing enteric-coated formulations believing they offer equivalent efficacy with better tolerance. This results in treatment failure that may be misattributed to patient non-compliance or inadequate dosing rather than the formulation itself 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.